Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

Immunotherapy has been incorporated into the first- and second-line treatment strategies for non-small cell lung cancer (NSCLC), profoundly ushering in a new treatment landscape. However, both adaptive signaling and oncogenic (epidermal growth factor receptor (EGFR)-driven) signaling may induce PD-L...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer
Hlavní autoři: Lin, Anqi, Wei, Ting, Meng, Hui, Luo, Peng, Zhang, Jian
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6745797/
https://ncbi.nlm.nih.gov/pubmed/31526368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-019-1062-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky